Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Cadila rises 4% on Mesalamine launch in US, FDA nod for Tranexamic & Pitavastatin

The USFDA also gave final approval to market Tranexamic acid injection, 1000mg/10 ml (100 mg/ml) single dose vial.

July 19, 2017 / 03:44 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Cadila Healthcare shares rallied nearly 4 percent on Wednesday after the launch of drug that used for the treatment of mild to moderate ulcerative colitis, in the US and the FDA approval for cholesterol and antifibrinolytic drugs.

Subsidiary Zydus Cadila has commercially launched its Mesalamine delayed release tablets (USP 1.2g) in the US market.

Zydus was the first to file an abbreviated new drug application (ANDA) for a generic version of Lialda and is currently the only generic available to patients in the US, the company said in its filing.

The group has received 26 final ANDA approval from the US Food & Drug Administration and 2 tentative ANDA approvals since January 2017.

Meanwhile, Zydus Pharma, the US division of Cadila Healthcare, has received approval from USFDA for Pitavastatin that helps in lowering bad cholesterol & raising good cholesterol.

The USFDA also gave final approval to market Tranexamic acid injection, 1000mg/10 ml (100 mg/ml) single dose vial.

Tranexamic acid is used to prevent or reduce bleeding in patients with haemophilia undergoing tooth extraction. The drug will be produced at the group's formulations manufacturing facility at Moraiya in Ahmedabad.

Posted by Sunil Shankar Matkar

first published: Jul 19, 2017 11:39 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347